We have reduced our full year (August) earnings estimate to $.20 a share. The long term outlook remains positive. The company's technology has a proven record in helping pharmaceutical companies develop new products more reliably and at lower cost. New applications are being developed. The sales force is expanding. And another demonstration project is in the pipeline. Performance could improve in future periods. Downside risk is limited by a $.20 a share cash dividend. Simulations Plus additionally is a prime acquisition candidate.
( Click on Table to Enlarge )